{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-002385","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.975550+00:00","generated_at":"2026-05-25T07:57:05.543264+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tenax raises $25M, expands Phase 3 LEVEL study to 230 patients, adds LEVEL-2 trial","bullets":["Private placement with RTW Investments grossed ~$25M; issued 378K shares + pre-funded warrants for 3.76M shares at $6.04/$6.03.","FDA accepted amendment to expand LEVEL study from 152 to 230 patients, increasing statistical power to >95%; enrollment expected by end of 2025.","FDA agreed to initiate second global Phase 3 LEVEL-2 study; first patient expected in 2025; primary endpoint 6MWD at 26 weeks.","Blinded LEVEL data shows >95% patients remain on therapy, no safety signals; topline data expected mid-2026.","Proceeds extend cash runway through end of 2027, funding Phase 3 trials and operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-002385","json":"https://secwatch.observer/filing/0001654954-25-002385.json","markdown":"https://secwatch.observer/filing/0001654954-25-002385.md","text":"https://secwatch.observer/filing/0001654954-25-002385.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495425002385/0001654954-25-002385-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495425002385/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T07:57:05.543264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}